

PCR-/NAT *Mycoplasma pneumoniae* (RV 541) Mai 2025



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

Proben Nr.	Erwartet / expected	Probenzusammensetzung / Sample composition
541A 250520 01	Ø	62 <i>Legionella pneumophila</i> SG1 (~ 5x10 ⁴ CFU/mL)
541A 250520 02	+++	61 <i>Mycoplasma pneumoniae</i> (~ 5x10 ⁵ genome copies/mL)
541A 250520 03	Ø	62 <i>Escherichia coli</i> K12
541A 250520 04	++	61 <i>Mycoplasma pneumoniae</i> (~ 5x10 ⁴ genome copies/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n</i> = 172	Proben Nr. (Sample no.)				Inhibition			
Befund Result	01	02	03	04	01	02	03	04
Positiv	2	172	1	172	n.d.	3	3	3
Negativ	170	0	171	0	nein no	169	169	169
Fraglich Questionable	0	0	0	0	ja yes	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number)	NAT richtig positiv True positive results				NAT richtig negativ True negative results			
	02		04		01		03	
	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%
AID CAP Bac PCR Kit (n = 5)	5	100	5	100	5	100	5	100
ARGENE Chla/Myco pneumo R-GENE (= 5)	5	100	5	100	5	100	5	100
Amplex eazypex PneumoBug expert (n = 4)	4	100	4	100	4	100	4	100
AmpliGnost M. pneumoniae (n = 2)	2	100	2	100	2	100	2	100
AmpliSens M.pn./C.pn. FRT Kit (n = 1)	1	100	1	100	1	100	1	100
AusDiagnostics Resp. Pathogens 24-well (n= 1)	1	100	1	100	1	100	1	100
BioGx auf BD Max (n = 9)	9	100	9	100	9	100	9	100
BioFire FILMARRAY Resp. Panel 2.1 plus (n= 2)	2	100	2	100	2	100	2	100

Biolegio ReadyMax b-CAP Assay (n = 1)	1	100	1	100	1	100	1	100
CerTest VIASURE C.pn, M.pn, L.pn (n= 6)	6	100	6	100	6	100	6	100
Respiratory Bacterial ELITe MGB Panel (n = 4)	4	100	4	100	4	100	4	100
GeneProof M. pneumoniae (n = 8)	8	100	8	100	8	100	8	100
EasyScreen Resp. Pathogen Detection (n= 1)	1	100	1	100	1	100	1	100
Luminex MagPix Resp. Pathogen (n = 3)	3	100	3	100	3	100	3	100
Luminex NxTAG Resp. Pathogen + SARS-CoV-2 (n = 2)	2	100	2	100	2	100	2	100
ampliCube Resp. panel 1.1 /1.1LC (n = 15)	15	100	15	100	15	100	15	100
Alethia Mycoplasma direct (n = 3)	3	100	3	100	3	100	3	100
QIAGEN QIAstat-Dx ME Panel (n = 3)	3	100	3	100	3	100	3	100
QIAstat-Dx Resp. Sars CoV-2 panel (n = 1)	1	100	1	100	1	100	1	100
Roche UC-TIB-Respi-BAC-2 (n= 8)	8	100	8	100	8	100	8	100
Sacace M.pn./C.pn. Real-TM (n = 1)	1	100	1	100	1	100	1	100
Sartorius Microsart ATMP Myc. (n = 3)	3	100	3	100	1	33	2	67
Seegene Allplex Pneumobacter (n = 14)	14	100	14	100	14	100	14	100
Seegene Allplex Resp. Panel 4 (n = 21)	21	100	21	100	21	100	21	100
TIB Molbiol LightMix M. pneumoniae (n = 8)	8	100	8	100	8	100	8	100
r-Biopharm RIDAGENE CAP Bac (n = 9)	9	100	9	100	9	100	9	100
r-Biopharm RIDAGENE M. pneumoniae (n = 1)	1	100	1	100	1	100	1	100
In house PCR assay (n = 24)	24	100	24	100	24	100	24	100
Other commercial tests (n = 7)	7	100	7	100	7	100	7	100

Comments:

1. The following tests are listed under "Other commercial tests": Altona FlexStar MP & CP PCR Detection Mix 1.5 (1x), Bioeksen (1x), Anatolia Geneworks Bosphore M. pneumoniae Detection Kit v1 (1x), USTAR Biotechnologies EasyNAT MP Assay (1x) and PathoFinder RespiFinder 2Smart (1x).